Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Ovarian Neoplasms 60Breast Neoplasms 21Neoplasms 19Fallopian Tube Neoplasms 16Prostatic Neoplasms 15Neoplasm Metastasis 9Pancreatic Neoplasms 8Endometrial Neoplasms 8Glioblastoma 7Triple Negative Breast Neoplasms 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Small Cell Lung Carcinoma 4Glioma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Mesothelioma 3Melanoma 3Head and Neck Neoplasms 3Cystadenocarcinoma, Serous 3Cholangiocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Sarcoma 2Prostatic Neoplasms, Castration-Resistant 2Ovarian Diseases 2Mesothelioma, Malignant 2

Interventions

pembrolizumab 5padeliporfin 5Nivolumab 5fludarabine 4aldesleukin 4Ipilimumab 4Cyclophosphamide 4atezolizumab 3Specimen Handling 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Carboplatin 3vedolizumab 2olaparib 2niraparib 2motexafin gadolinium 2cabozantinib 2anlotinib 2abiraterone 2Therapeutics 2Sunitinib 2Standard of Care 2Riluzole 2Radiation Dose Hypofractionation 2Prednisone 2Pluvicto 2Mitomycin 2LDP-02 2Infliximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Urogenital Neoplasms × niraparib × Clear all
NCT04556071 2020-11-10

AVANIRA3

Jiangsu Cancer Institute & Hospital

Phase 2 Unknown
32 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT00749502 2013-07-25

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)

Tesaro, Inc.

Phase 1 Completed
113 enrolled
GenitourinaryGynecologicLymphoidOther hematologic neoplasm

Adnexal Diseases, Endocrine System Diseases, Endocrine Gland Neoplasms, Genital Diseases, Female, Genital Diseases, Male, Genital Neoplasms, Female, Genital Neoplasms, Male, Gonadal Disorders, Neoplasms, Ovarian Diseases, Ovarian Neoplasms, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡